Format

Send to

Choose Destination
Clin Exp Metastasis. 2018 Aug;35(5-6):503-520. doi: 10.1007/s10585-018-9913-y. Epub 2018 Jul 17.

Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs.

Author information

1
California Pacific Medical Center Research Institute, 2333 Buchanan St., San Francisco, CA, 94115, USA.
2
California Pacific Medical Center Research Institute, 2333 Buchanan St., San Francisco, CA, 94115, USA. kimkb@sutterhealth.org.

Abstract

Malignant melanoma is generally chemo- and radio-resistant, and patients with advanced melanoma have a poor prognosis. However, with our increased understanding of the checkpoint immune molecules and genetic alterations of melanoma cells, more effective immunotherapy, such as anti CTLA4 antibody and anti PD-1 antibodies, and targeted drug therapy, such as BRAF inhibitors and MEK inhibitors, have been developed, resulting in improved overall survival and quality of life of patients with advanced melanoma. In addition, emerging technologies to develop prognostic and predictive biomarkers for response to systemic therapy could help clinicians make more accurate assessments of the disease and formulate more effective treatment plans. In this review, current standard systemic therapy options and recently developed novel drugs for advanced melanoma are discussed.

KEYWORDS:

BRAF mutation; CTLA-4; Checkpoint inhibitor; Melanoma; PD-1; Targeted therapy

PMID:
30019239
DOI:
10.1007/s10585-018-9913-y
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center